Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials – Supplementary Materials

Supplementary Materials for the manuscript titled 'Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials'.

Includes a plain language summary (PLS) of the manuscript, a summary of hematology and biochemistry assessment schedules (Supplementary Table 1), EAIRs of laboratory elevations in ALT or AST >3x and >5x ULN with bimekizumab, placebo, and active comparators (Supplementary Table 2), and a summary of relevant medical history, concomitant medications, and confounding factors in patients with instances of laboratory elevations in ALT or AST >5x ULN (Supplementary Table 3).